Citations

Clear

6274 citation(s) found for "To, Andrew".

Pneumocystis carinii glycoprotein A binds macrophage mannose receptors
O’Riordan, Deirdre , Standing, Joseph E., Limper, Andrew H.

Mayo Clinic

Infection and Immunity | January 6, 2020 | Volume: 63 | Issue: 3 | Pages: 779-784

10.1128/iai.63.3.779-784.1995 | PMID 7868247 Get It

Pneumocystis carinii causes life-threatening pneumonia in patients with impaired immunity. Recent studies suggest that alveolar macrophages interact with P. carinii through macrophage mannose receptors. However, the ligand(s) on P. carinii that is recognized by these receptors has not been fully defined. P. carinii contains a major mannose-rich surface antigen complex termed glycoprotein A (gpA). It was therefore hypothesized that gpA binds directly to macrophage mannose receptors and mediates organism attachment to these phagocytes. To assess this, gpA was purified from P. carinii by continuous-elution gel electrophoresis. 125I-labeled gpA bound to alveolar macrophages in a saturable fashion. In addition, gpA binding was substantially inhibited by both alpha-mannan and EDTA, further suggesting that gpA interacts with macrophage mannose receptors. Macrophage membrane proteins capable of binding to gpA were isolated with a gpA-Sepharose column. A 165-kDa membrane-associated protein was specifically eluted from the gpA-Sepharose column with EDTA (20 mM). This protein was identified as the macrophage mannose receptor by immunoprecipitation with a polyclonal anti-mannose receptor antiserum. To further investigate the role of gpA in P. carinii-macrophage interactions, 51Cr-labeled P. carinii cells were incubated with macrophages in the presence of increasing concentrations of soluble gpA, and organism attachment was quantified. Soluble gpA (2.5 mg/dl) competitively inhibited P. carinii attachment to alveolar macrophages by 51.3% +/- 3.7% (P = 0.01). Our findings demonstrate that gpA present on P. carinii interacts directly with mannose receptors, thereby mediating organism attachment to alveolar macrophages.
International multicentre review of perioperative management and outcome for catecholamine-producing tumours
Groeben, Harald , Walz, Martin K. , Nottebaum, B J, Alesina, Pier Francesco , Greenwald, Andrew, Hollmann, Markus W. , Schwarte, Lothar A. , Behrends, Matthias , Rössel, Thomas , Groeben, Christer , Schäfer, Maximilian, Lowery, Aoïfe , Yamakage, Michiaki , Miller, Julie Ann , Cherry, Tiffany J. , Nelson, Amanda, Solórzano, Carmen C. , Gigliotti, Benjamin J. , Wang, T. S., Wietasch, G. , Graham, Paul H. , Schaefer, Maximilian S. , Groeben, H , Sprung, J , Schumann, Roman , Hirata, Naoyuki , Friederich, P, Sheppard, Brett C. , Weingarten, Toby N. , Šprung, Juraj

Mayo Clinic

British Journal of Surgery | January 6, 2020 | Volume: 107 | Issue: 2 | Pages: e170-e178

10.1002/bjs.11378 | PMID 31903598 Get It

Abstract Background Surgery for catecholamine-producing tumours can be complicated by intraoperative and postoperative haemodynamic instability. Several perioperative management strategies have emerged but none has been evaluated in randomized trials. To assess this issue, contemporary perioperative management and outcome data from 21 centres were collected. Methods Twenty-one centres contributed outcome data from patients who had surgery for phaeochromocytoma and paraganglioma between 2000 and 2017. The data included the number of patients with and without α-receptor blockade, surgical and anaesthetic techniques, complications and perioperative mortality. Results Across all centres, data were reported on 1860 patients with phaeochromocytoma or paraganglioma, of whom 343 underwent surgery without α-receptor blockade. The majority of operations (78·9 per cent) were performed using minimally invasive techniques, including 16·1 per cent adrenal cortex-sparing procedures. The cardiovascular complication rate was 5·0 per cent overall: 5·9 per cent (90 of 1517) in patients with preoperative α-receptor blockade and 0·9 per cent (3 of 343) among patients without α-receptor blockade. The mortality rate was 0·5 per cent overall (9 of 1860): 0·5 per cent (8 of 517) in pretreated and 0·3 per cent (1 of 343) in non-pretreated patients. Conclusion There is substantial variability in the perioperative management of catecholamine-producing tumours, yet the overall complication rate is low. Further studies are needed to better define the optimal management approach, and reappraisal of international perioperative guidelines appears desirable.
Targeting epigenetic regulators in the treatment of T-cell lymphoma
Ahmed, Nada, Feldman, Andrew L.

Mayo Clinic

Expert Review of Hematology | January 4, 2020 | Volume: 13 | Issue: 2 | Pages: 127-139

10.1080/17474086.2020.1711732 | PMID 31903826 Get It

Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through alpha-mannan and beta-glucan cell wall components
Castro, M.A., Rohrbach, Michael S., Castro, M, Ralston, Nicholas V.C. , Morgenthaler, Timothy I. , Limper, Andrew H.

Mayo Clinic

Infection and Immunity | January 3, 2020 | Volume: 62 | Issue: 8 | Pages: 3138-3145

10.1128/iai.62.8.3138-3145.1994 | PMID 8039882 Get It

Candida albicans is an increasingly important fungal pathogen. Alveolar macrophages respond to fungal components such as zymosan by releasing arachidonic acid (AA) and AA metabolites. However, few studies hypothesized that macrophages respond to C. albicans by releasing AA and generating AA metabolites as a consequence of interaction of mannose and beta-glucan receptors with fungal cell wall components. [14C]AA-labeled rabbit alveolar macrophages released AA following stimulation with either live or heat-killed C. albicans. High-pressure liquid chromatography analysis revealed that 55% of the AA released was metabolized via cyclooxygenase and lipoxygenase pathways. The metabolites consisted of prostaglandin E2, prostaglandin F2 alpha, 6-ketoprostaglandin F1 alpha, thromboxane B2, and leukotrienes B4 and D4. We further examined the roles of alpha-mannan and beta-glucan components of C. albicans in mediating these alterations of eicosanoid metabolism. Prior work in our laboratory has shown that soluble alpha-mannan and beta-glucan inhibit macrophage mannose and beta-glucan receptors, respectively. Incubation of alveolar macrophages with soluble alpha-mannan derived from C. albicans (1 mg/ml) resulted in 49.8% +/- 2.6% inhibition of macrophage AA release during stimulation with intact C. albicans (P = 0.0001 versus control). Macrophage AA release in response to C. albicans was also inhibited to a significant but lesser degree by soluble beta-glucan (36.2% +/- 1.3%; P = 0.008 versus control). These results indicate that C. albicans stimulates macrophage AA metabolism and that these effects are partly mediated by alpha-mannan and beta-glucan constituents of the fungus.
Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells
Standing, Joseph E., Hoffman, O A, Castro, M.A., Neese, L W, Limper, Andrew H. , Castro, M

Mayo Clinic

Infection and Immunity | January 3, 2020 | Volume: 61 | Issue: 10 | Pages: 4302-4309

10.1128/iai.61.10.4302-4309.1993 | PMID 7691747 Get It

Pneumocystis carinii attaches to alveolar epithelial cells during the development of pneumonia. Adhesive proteins found within the alveolar space have been proposed to mediate P. carinii adherence to lung cells. Vitronectin (Vn), a 75-kDa glycoprotein present in the lower respiratory tract, has substantial cell-adhesive properties and might participate in the host-parasite interaction during P. carinii pneumonia. To address whether Vn binds to P. carinii, we studied the interaction of radiolabeled Vn with purified P. carinii organisms. Vn bound to P. carinii, occupying an estimated 5.47 x 10(5) binding sites per organism, with an affinity constant, Kd, of 4.24 x 10(-7) M. Interestingly, the interaction of Vn with P. carinii was not mediated through the Arg-Gly-Asp cell-adhesive domain of Vn. Addition of Arg-Gly-Asp-Ser (RGDS) peptides did not inhibit binding. In contrast, Vn binding to P. carinii was substantially inhibited by the addition of heparin or by digesting the organisms with heparitinase, suggesting that P. carinii may interact with the glycosaminoglycan-binding domain of Vn. To determine whether Vn might enhance P. carinii attachment to lung epithelial cells, we studied the binding of 51Cr-labeled P. carinii to cultured A549 lung cells. Addition of Vn resulted in significantly increased binding of P. carinii to A549 cells, whereas a neutralizing anti-Vn serum substantially reduced the binding of P. carinii to A549 cells. These data suggest that Vn binds to P. carinii and that Vn might provide an additional means by which P. carinii attaches to respiratory epithelial cells.
Diffuse epithelioid malignant mesothelioma of the pleura presenting as a hydropneumothorax and vertebral body invasion
Hinkamp, Colin , Dalal, Shanup N , Butt, Yasmeen M. , Chan, Alberto V. Cabo, Hinkamp, Colin Andrew , Butt, Yasmeen

Mayo Clinic

BMJ Case Reports | January 3, 2020 | Volume: 13 | Issue: 1 | Pages: e231987

10.1136/bcr-2019-231987 | PMID 31900296 Get It

Malignant mesothelioma is an uncommon form of neoplastic transformation of the mesothelial cells that line the serosal surfaces of the body. It most commonly affects the pleura and is often associated with pleural effusions and pleural-based masses. The annual incidence in the United States is only 3300 cases, representing less than 0.3% of all cancers worldwide, although this is likely underestimated. We present a case of diffuse epithelioid malignant pleural mesothelioma in a patient with remote, short-term asbestos exposure complicated by recurrent left-sided hydropneumothoraces and pleural-based invasion of the T12 vertebral body, which represent two rare coexisting complications. This case illustrates the importance of maintaining a broad differential for hydropneumothorax, particularly as the risk factors may be decades removed and the degree of asbestos exposure to induce a malignant mesothelioma may be smaller than has been traditionally thought.
Analytical Performance and Clinical Utility of a Nucleic Acid Sequence-Based Amplification Assay for Detection of Cytomegalovirus Infection
Witt, Donald J., Kemper, Marti, Stead, Andrew, Sillekens, Peter, Ginocchio, Christine C. , Espy, Mark J., Payá, Carlos V., Smith, Thomas F., Roeles, Frits, Caliendo, Angela M.

Mayo Clinic

Journal of Clinical Microbiology | December 31, 2019 | Volume: 38 | Issue: 11 | Pages: 3994-3999

10.1128/jcm.38.11.3994-3999.2000 | PMID 11060058 Get It

ABSTRACT A nucleic acid sequence-based amplification (NASBA) assay for qualitative detection of human cytomegalovirus (CMV) pp67 mRNA was evaluated in a multicenter study. Negative results were obtained for all specimens from 50 CMV-seronegative and 50 CMV-seropositive low-risk whole-blood donors. No interference with CMV mRNA amplification was observed in the testing of 288 specimens containing various potential interfering substances, nonspecifically reacting substances (including mRNA from other herpesviruses), and three anticoagulants. A total of 95% (50 of 51) of CMV-positive (cell culture- and antigenemia immunofluorescence [AG-IFA]-positive) clinical specimens were positive by the NASBA assay. Results from different operators over multiple testing days were consistent for each of four panel members containing different concentrations of CMV mRNA, indicating the reproducibility of the assay. The estimated 95% reliable upper detection limit of the assay was 600 mRNA copies; the lower limit of detection was less than 25 mRNA copies. The clinical utility of the assay was evaluated with longitudinally collected specimens from solid-organ transplant patients ( n = 21). A total of 98% (81 of 83) of the specimens from CMV-negative patients were negative by the NASBA assay, while 90% (10 of 11) of patient specimens that were positive by cell culture or AG-IFA were positive by the NASBA assay. Positive NASBA assay results were obtained earlier than AG-IFA or cell culture results for 55% of the patients and at the same time for the remainder of the patients (45%). The overall agreement between the NASBA assay and current reference tests was 86% when active CMV infection was present. These studies indicate that the CMV pp67 mRNA NASBA assay has reproducible and sensitive performance characteristics that should enable more rapid diagnosis of CMV infection.
Analysis of Pneumocystis carinii Introns
Thomas, Charles F., Leof, Edward B. , Limper, Andrew H.

Mayo Clinic

Infection and Immunity | December 31, 2019 | Volume: 67 | Issue: 11 | Pages: 6157-6160

10.1128/iai.67.11.6157-6160.1999 | PMID 10531280 Get It

ABSTRACT Pneumocystis carinii is an ascomycete phylogenetically related to Schizosaccharomyces pombe . Little is known about gene regulation in P. carinii . The removal of introns from pre-mRNA requires spliceosomal recognition of the intron-exon boundary. In S. pombe and higher eukaryotes, this boundary and a branch site within the intron are conserved. We recently demonstrated that P. carinii cdc2 cDNA can complement S. pombe containing conditional mutations of cdc2 , an essential gene involved in cell cycle regulation. We next tested whether P. carinii genomic cdc2 (with six introns) could also complement S. pombe cdc2 mutants and found genomic sequences incapable of this activity. Reverse transcriptase PCR confirmed the inability of the S. pombe cdc2 mutants to splice the P. carinii genomic cdc2 . Analysis of 83 introns from 19 P. carinii protein-encoding genes demonstrated that the sequence GTWWDW functions as a donor consensus in P. carinii , whereas YAG serves as an acceptor consensus. These sequences are similar in S. pombe ; however, a branch site sequence was not found in the P. carinii genes studied.
The need for novel trial designs, master protocols, and research consortia in transplantation
Stegall, Mark D. , Smith, Byron H. , Bentall, Andrew , Schinstock, Carrie A. , Smith, Byron , Schinstock, Carrie , Stegall, Mark D , Bentall, Andrew

Mayo Clinic

Clinical Transplantation | December 31, 2019 | Volume: 34 | Issue: 1 | Pages: No page available

10.1111/ctr.13759 | PMID 31889338 Get It

AbstractLarge multicenter, randomized controlled trials are the paradigm for determining the efficacy and safety of new therapies. However, applying this classical approach to many areas of transplantation is difficult. For most types of organ transplants, the number of transplants performed is too small for such a trial (lung, pancreas, or vascular composite transplantation are examples). In larger populations such as kidney transplantation, the major unmet needs commonly involve small subsets of patients (antibody‐mediated rejection, recurrent renal disease, etc). This issue is not unique to transplantation and has been successfully overcome in other areas of medicine. In oncology, for example, novel trial designs such as adaptive trial design and master protocols are now relatively common. In addition, the existence of multicenter, ongoing clinical research consortia have greatly enhanced the successful implementation of these novel trial designs. In this manuscript, we examine how novel trial designs, master protocols, and research consortia might enhance studies in transplantation aimed at the regulatory approval of new agents. Our premise is that more efficient approaches to clinical trials already exist and, through a coordinated effort by researchers, the pharmaceutical industry, and regulatory bodies like the FDA, they can be implemented in transplantation.
Authors' Reply
Rule, Andrew D. , Jager, Kitty J. , Delanaye, Pierre , Delanaye, Pierre , Rule, Andrew D , Jager, Kitty J , Brand, Jan A.J.G. van den

Mayo Clinic

Journal of the American Society of Nephrology | December 23, 2019 | Volume: 31 | Issue: 2 | Pages: 448-449

10.1681/asn.2019111188 | PMID 31871273 Get It